Evidence map›Paper›PMID 38525250›Full record

ArticleEngineering biology2024

Building the bioeconomy: A targeted assessment approach to identifying biobased technologies, challenges and opportunities.

Claire Holland, Philip Shapira

Abstract read
In one paragraph

Article in Engineering biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Claire HollandManchester Institute of Innovation Research Alliance Manchester Business School University of Manchester Manchester UK.ORCID https://orcid.org/0000-0002-1537-9821
Philip ShapiraManchester Institute of Innovation Research Alliance Manchester Business School University of Manchester Manchester UK.ORCID https://orcid.org/0000-0003-2488-5985

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The authors explore opportunities, challenges, and strategies to translate and responsibly scale innovative biobased technologies to build more sustainable bioeconomies. The pandemic and other recent disruptions increased exposure to issues of resilience and regional imbalance, highlighting a need for production and consumption regimes centred more on local biobased resources and dispersed production. The authors review potential biobased technology strategies and identify promising and feasible options for the United Kingdom. Initial landscape and bibliometric analysis identified 50 potential existing and emerging biobased technologies, which were assessed for their ability to fulfil requirements related to biobased production, national applicability, and economic-, societal-, and environmental-benefits, leading to identification of 18 promising biobased production technologies. Further analysis and focus-group discussion with industrial, governmental, academic, agricultural, and social stakeholders, identified three technology clusters for targeted assessment, drawing on cellulose-, lignin-, and seaweed feedstocks. Case studies were developed for each cluster, addressing conversations around sustainable management, use of biomass feedstocks, and associated environmental-, social-, and economic challenges. Cases are presented with discussion of insights and implications for policy. The approach presented is put forward as a scalable assessment method that can be useful in prompting, informing, and advancing discussion and deliberation on opportunities and challenges for biobased transformations.

Indexed as

bio‐economyindustryresponsible research innovationscale‐up strategiessynthetic biology

Identifiers

PMID38525250
PMCPMC10959757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.